Identification of interleukin-6 trans-signalling as a novel target for therapeutic approaches to lung cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1063998

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Interleukin-6 (IL-6) has been implicated as a causative factor in lung cancer, the most lethal cancer worldwide, albeit by unknown mechanisms. Since IL-6 is also important for immune system homeostasis, the development of anti-IL-6 therapies requires an intimate knowledge of pathological versus physiological IL-6 signalling pathways. This project aims for the first time to define an alternative IL-6 signalling pathway, termed “trans signalling”, in the molecular pathogenesis of lung cancer.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2016

Funding Scheme: Project Grants

Funding Amount: $627,089.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Molecular Targets

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cytokine signalling | interleukin-6 (IL-6) | lung cancer | lung inflammation | mouse models | therapeutic agents

Related Links